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Background: Hypoxia inducible factor-1 has been identified as a potential target to overcome hypoxia-induced radioresistance 
The aim of the present study was to investigate whether selective HIF-1 inhibition via small interfering RNA (siRNA) targeting 
hypoxia-inducible factor 1α (HIF-1α) affects hypoxia-induced radioresistance in HT 1080 human fibrosarcoma cells.
Material and Methods: HIF-1α expression in HT 1080 human fibrosarcoma cells in vitro was silenced using HIF-1α siRNA se-
quence primers. Quantitative real-time polymerase chain reaction assay was performed to quantify the mRNA expression of HIF-
1α. HIF-1α protein levels were studied by Western blotting at 20% (air) or after 12 hours at 0.1% O2 (hypoxia). Cells were assayed for 
clonogenic survival after irradiation with 2, 5, or 10 Gy, under normoxic or hypoxic conditions in the presence of HIF-1α-targeted 
or control siRNA sequences. A modified oxygen enhancement ratio (OER´) was calculated as the ratio of the doses to achieve the 
same survival at 0.1% O2 as at ambient oxygen tensions. OER´ was obtained at cell survival levels of 50%, 37%, and 10%.
Results: HIF-1α-targeted siRNA enhanced radiation treatment efficacy under severely hypoxic conditions compared to tumor 
cells treated with scrambled control siRNA. OER was reduced on all survival levels after treatment with HIF-1α-targeted siRNA, 
suggesting that inhibition of HIF-1 activation by using HIF-1α-targeted siRNA increases radiosensitivity of hypoxic tumor cells in 
vitro.
Conclusion: Inhibition of HIF-1 activation by using HIF-1α-targeted siRNA clearly acts synergistically with radiotherapy and in-
crease radiosensitivity of hypoxic cells in vitro.
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Hypoxia-inducible-Factor-1α-Small-Interfering-RNA inhibiert die hypoxische Akkumulation von HIF-1α und erhöht 
die Strahlensensitivität von HT-1080-Fibrosarkomzellen in vitro
Hintergrund und Ziel: Hypoxia-inducible Factor-1 (HIF-1) wurde als potentielles therapeutisches Target identifiziert. Ziel der 
Arbeit war es, zu untersuchen, ob die selektive HIF-1-Inhibition mittels Small Interfering RNA (siRNA) gegen HIF-1α die Strahlen-
sensibilität von hypoxischen HT-1080-Zellen beeinflussen kann.
Material und Methodik: Die HIF-1α-Expression in humanen HT-1080-Fibrosarkomzellen wurde mittels RNA-Interferenz nach 
Transfektion der Zellen mit siRNA unter hypoxischen Bedingungen (0,1% O2, 12 h), bzw. Normoxie (20% O2) in vitro inhibiert. Die 
HIF-1α-Genexpression wurde mit quantitativer Realtime-Polymerasekettenreaktion (qRT-PCR), das HIF-1α-Protein mittels Wes-
tern Blot quantifiziert. Das klonogene Überleben wurde nach Bestrahlung unter Hypoxie und Normoxie bestimmt und daraus 
eine Oxygen Enhancement Ratio (OER´) bei den Überlebensniveaus 50%, 37% and 10% berechnet.
Resultate: HIF-1α-siRNA erhöht die Strahlensensibilität unter hypoxischen Bedingen, verglichen mit HT-1080-Zellen, die mit 
Kontroll-siRNA behandelt wurden. Die OER` war bei allen Überlebensniveaus reduziert.
Schlussfolgerung: Eine selektive Inhibition der HIF-1-Aktivierung durch HIF-1α-siRNA wirkt synergistisch mit einer Bestrahlung 
und erhöht die Strahlensensitivität hypoxischer Tumorzellen in vitro.
Schlüsselwörter: Hypoxia-inducible factor-1α · Small Interfering RNA · Hypoxie · Bestrahlung · Sauerstoff
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Background
Hypoxia is a common feature of solid tumors that profoundly 
affects the biological behavior, response to therapy, and prog-
nosis of human cancers [10, 31]. Despite of improvements in 
chemo- and radiotherapy, long-term prognosis is still poor for 
many patients with newly diagnosed or recurrent cancer dis-
eases [3, 28, 36, 38].
Several reports have demonstrated an increased chemore-
sistance [4, 5] and radioresistance [21] in hypoxic tumor cells 
resulting from activation of the hypoxia-inducible factor-1 
(HIF-1) pathway. The HIF-1 system is a key regulator of a broad 
range of cellular and systemic responses to hypoxia and acts in 
all mammalian cells.
The transcription factor HIF-1 is a heterodimer formed by 
the association of an oxygen-regulated HIF-1α subunit with a 
constitutively expressed HIF-1β subunit [22, 34]. Degradation 
of HIF-1α is O2 dependent. Under normoxic conditions, HIF-
1α is degraded by the activity of prolyl hydroxylases [12, 13]. 
Under hypoxic conditions, the rates of hydroxylation and ubiq-
uitination decline, resulting in an accumulation of HIF-1α [7].
Associations between high levels of protein expression of 
HIF-1α in tumor tissues [30] and poor prognosis have been 
shown in patients with breast cancer [29], head and neck can-
cer [1, 14] cervical cancer [6], esophagus [20], stomach [9], and 
non-small cell lung cancer [17]. Increased expression of HIF-
1α protein is, therefore, an independent predictor of poor prog-
nosis and poor response to treatment in most types of cancer. 
In particular, high expression of HIF-1α or HIF-1-regulated 
proteins, such as glucose transporter 1 (GLUT-1) or carbonic 
anhydrase IX (CA IX), is associated in most series not only with 
survival endpoints but also with locoregional control after radi-
cal radiotherapy, suggesting a direct link between the expres-
sion of these proteins and hypoxia-related radioresistance of 
tumor cells [2]. We were previously able to show in HT 1080 
human fibrosarcoma cells that targeting HIF-1 function phar-
macologically with chetomin sensitized hypoxic cells to single-
dose radiotherapy. However, this approach was impaired by rel-
evant cytotoxicity of the agent and a rather unspecific action of 
the compound inhibiting the interaction of HIF-1 and the tran-
scriptional coactivator p300 [25]. The aim of the present study 
was to investigate if selective HIF-1 inhibition by using small 
interfering RNA (siRNA) targeting HIF-1a affects hypoxia-
induced radioresistance in human tumor cells.
Material and Methods
Cell Culture
Early-passage HT 1080 human fibrosarcoma cells from the 
American Type Culture Collection (ATCC, Rockville, MD) 
were maintained under standard conditions as previously 
 described [32]. Cells were cultured in MEM supplemented 
with 10% fetal bovine serum and 100,000 U/L penicillin and 
100 mg/L streptomycin (all from Sigma, St. Louis, MO, USA) 
with 5% CO2 in a well-humidified incubator. For hypoxia 
experiments, early-passage cells were split and seeded into 
80-mm glass Petri dishes at 1.0 × 106 cells per dish. On the fol-
lowing day, when the cells were still in the exponential growth 
phase, they were transferred without further medium change to 
a Ruskinn (Cincinnati, OH, USA) Invivo2 hypoxic workstation 
for hypoxia treatment. The oxygen concentration of 0.1% was 
achieved inside the workstation before transferring the cells by 
calibrating the oxygen probe against air according to the manu-
facturer’s instructions; adjusting the instrument settings to the 
desired O2 concentration, 5% CO2 and 37 °C; and subsequent 
flooding of the chamber with an appropriate gas mixture of 
pressurized air, N2, and CO2 through an automated gas mixing 
module. Aerobic conditions were maintained in the incubator 
at 5% CO2 and 20% O2. Where indicated siRNA against HIF-1α 
(Qiagen, Hilden, Germany) was used.
Different siRNAs were assayed in pilot flow cytometry ex-
periments. In RT-PCR and clonogenic survival experiments, 
siRNA was added at a concentration of 133 nM to medium 
4  hours before treatment with hypoxia. Then after 4  hours, 
when HT 1080 cells became adherent, HT 1080 cells were 
transferred to the hypoxic workstation (0.1% O2, 12 hours) or 
to the well-humidified incubator (12 hours) without changing 
medium. HT 1080 cells were, thus, treated for 16 hours with 
siRNA (133 nM) prior to radiation treatment.
Flow Cytometry of 5HRE-hCMVmp-EGFP HT 1080 Cells
To study the effect of different HIF-1α-targeted or control siR-
NA sequences on hypoxia-responsive element (HRE) binding 
of HIF-1 and gene transactivation, we used HT 1080 cells stably 
transfected with enhanced green fluorescent protein (EGFP) 
under the control of a hypoxia-responsive promoter containing 
five copies of a hypoxia-responsive element from the human 
vascular endothelial growth factor (VEGF) gene. HT 1080 cells 
transfected with the same EGFP under the control of a strong 
constitutive, hypoxia-independent CMV promoter were used 
as positive controls as described previously (both cell types 
kindly provided by J.M. Brown, Stanford University, CA, USA) 
[32]. The design of the constructs and their application as a re-
porter system of tumor hypoxia has been previously reported 
[23].
Cells were exposed to experimental conditions as for 
PCR experiments in glass Petri dishes. Due to the known re-
quirement of sufficient reoxygenation for the development of 
hypoxia-dependent, HRE-mediated EGFP fluorescence, all 
samples were returned to aerobic conditions in the incubator 
for 4 hours before FACS analysis as previously described [32]. 
EGFP fluorescence was measured on a FacsCalibur flow cy-
tometer (Becton Dickinson) as described previously [2]. Dead 
cells and debris were gated out on the basis of forward and side 
scatter dot plots.
RT-PCR
Quantitative real-time polymerase chain reaction (RT-PCR) 
assay was performed using the LightCycler instrument and the 
SybrGreen detection system (both from Roche Diagnostics, 
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Mannheim, Germany) to quantify the mRNA expression of 
HIF-1α. Total RNA was purified from 1.0 × 106 HT 1080 cells 
with use of RNeasy Mini kit (Qiagen, Hilden, Germany) ac-
cording to the manufacturer’s instructions. RNA was eluted in 
30 μl RNase-free water.
First-strand cDNA was synthesized from 900 ng total RNA 
with use of Quantitect Reverse Trancriptase Kit (Qiagen) ac-
cording to the protocol of the manufacturer.
For the amplicon detection, the LightCycler Sybr-Green 
kit (Roche Diagnostics, Mannheim, Germany) was used and 
supplemented with 4 mM MgCl2 and 0.5 μM (each) of the 
HIF-1α-specific primers (5'-CTC AAA GTC GGA CAG CCT 
CA-3', 5'-CCC TGC AGT AGG TTT CTG CT-3'). PCR was 
carried out in 20-μl capillaries (2 μl/4 μg of cDNA and 18 ml 
of master-mix) at 95 °C for 30 s, followed by 50 cycles of 15 s at 
50 °C, 15 s at 72 °C. Genotyping was performed by melting 
curve analysis: 50 °C for 15 s, followed by a temperature in-
crease from 50 °C to 95 °C (0.2 °C/s) with continuous fluo-
rescence recording on channel F1. Each assay run included 
a reagent control containing water instead of sample cDNA. 
All assays were performed in three replicates. For normaliza-
tion, we used the β2-microglobulin housekeeping gene set 
(Roche Diagnostics). Amplification was carried out by using 
the FastStart Master Hybridization Probes kit (Roche Diag-
nostics) with the following parameters: 95 °C for 9 s, 55 °C 
for 15 s, 72 °C for 20 s. 45 cycles were performed. The con-
trol sample consisting of unstimulated cells under normoxia 
was set to be 1. Cells under hypoxia, stimulated with HIF-1α-
targeted or control siRNA, were compared with the control 
sample.
Small Interfering RNA (siRNA) Treatment and  
Transfection
Approximately 1.0 × 106 HT-1080 carcinoma cells were gent-
ly resuspended in 100 µl MEM at room temperature. HT 1080 
cells were electroporated (Elektroporations-Impulsgenerator 
0–2500 V (EPI 2500) (Dr. Fischer, Heidelberg, Germany) with 
133 nM double-stranded antisense oligonucleotides specific for 
HIF-1α mRNA. A protein expression analysis, gene expression 
analysis, FACS analysis and in vitro clonogenic assay were all 
performed 16 hours after siRNA transfection.
HIF-1α expression was silenced using designed HIF-1α 
siRNA sequence primers (Qiagen, Hilden, Germany) that were 
transfected into HT 1080 cells according to the manufacturer’s 
instructions. Briefly, HIF-1α-targeted or control siRNA se-
quences were added to HT 1080 cells at a final concentration of 
133 nM, (siRNA3: HIF-1α sense r(CCA UUU ACA UAA UAU 
AGA A)dTdt targeting AGC CAT TTA CAT AAT ATA GAA of 
the human HIF-1α mRNA. siRNA4: HIF-1α sense r(CCG AAU 
UGA UGG GAU AUG A)dTdt targeting TAC CGA ATT GAT 
GGG ATA TGA of the human HIF-1α mRNA)).
Cells transfected with scrambled control siRNA (Qiagen: 
AllStars Neg. Control siRNA, Catalog no. 1027281) were used 
as a negative control.
Radiation Treatment and Clonogenic Assay
Immediately after the 12-hour hypoxia treatment or control 
treatment (±siRNA133 nM), the glass culture dishes were en-
closed in Perspex shells inside the hypoxic workstation and 
transferred to the linear accelerator. Cells were irradiated with 
a dose of 2, 5, or 10 Gy (dose rate 2.5 Gy/min, 6 MV photons, 
room temperature, adequate Perspex bolus). Aerobic cells were 
irradiated in similar Perspex shells with holes permitting un-
impaired air exchange. Cell survival was quantified by stan-
dardized colony-forming assay. HT 1080 cells from untreated 
or irradiated monolayers were trypsinized and resuspended 
immediately after treatment, seeded in culture flasks in ap-
propriate dilutions. On day 14, cells were stained with crystal 
violet, and colonies consisting of at least 50 cells were counted. 
The plating efficiency (PE) was expressed as the percentage of 
colonies relative to the number of cells seeded. The ratio of PE 
of irradiated and respective control cells, correcting for differ-
ences in plating efficiency of unirradiated cells, gave the relative 
survival (S). Survival curves were generated by plotting S as a 
function of radiation dose (D). The survival data were fitted 
with the linear-quadratic model: S(D) = exp [–(αD + βD2)] by 
optimizing variable parameters α and β [10]. A modified oxy-
gen enhancement ratio (OER') was calculated as the ratio of 
the doses to achieve the same survival at 0.1% O2 as at ambient 
oxygen tensions: OER’ = Dhypoxia/Dnormoxia. OER’ was ob-
tained at cell survival levels of 50%, 37%, and 10%.
Western Blot Analysis
At the end of the 16-hour in vitro treatment under different 
conditions, Petri dishes were immediately placed on ice. HIF-
1α protein and β-tubulin protein were quantified in Western 
blots of nuclear extracts as previously described [31]. For quan-
tification of HIF-1α protein content, the ratio of HIF-1α and 
β-tubulin band densities of a control sample transfected with 
scrambled control siRNA under hypoxic conditions (0.1% O2, 
12 hours) HT 1080 cells, aliquots of which were run with each 
blot, were defined as 100% and used as a reference for quanti-
fication. Means ± standard deviations (SD) were calculated for 
each condition.
Statistical Analysis
Expression levels of mRNA and clonogenic survival were 
compared between treatment groups by Mann-Whitney U 
test using Statistica vs. 6.1 (Statsoft, Tulsa, OK, USA) software 
(p < 0.05 considered significant).
Results
Effects of HIF-1 -Targeted siRNA (siRNA 3 and siRNA4) 
on HIF1α mRNA Expression
Transfection of HT 1080 tumor cells with HIF-1α-targeted siR-
NA (siRNA3 and siRNA4) caused a significantly reduced ex-
pression of HIF-1α mRNA compared to untreated control cells 
and HT 1080 cells transfected with scrambled control siRNA 
(Figure 1). The mean HIF-1α mRNA expression was reduced 
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after transfection with scrambled siRNA to 69.9 ± 5.7% com-
pared to untreated HT 1080 cells (100%). Transfection with 
siRNA3 or siRNA4 reduced the mean ± SD HIF-1α mRNA ex-
pression to 7.4 ± 1.9% and 5.6 ±1.5%, respectively, compared to 
the untreated control (100%).
Effects of siRNA on HIF-1-Dependent Transcriptional 
Activation
Transfection of HT 1080 cells with HIF-1α-targeted siRNA 
(siRNA3 and 4) inhibited the hypoxic activation of HRE-me-
diated EGFP fluorescence in stably transfected HT 1080 hu-
man fibrosarcoma cells (Figure 2). A maximum suppression of 
EGFP fluorescence signal was measured when HT 1080 cells 
were transfected with siRNA3 and siRNA4 4–8 hours prior to 
hypoxia treatment (0.1% O2, 12 hours) and at a final concentra-
tion of 133 nM (data not shown).
siRNA3 suppressed the hypoxic increase in EGFP fluores-
cence significantly to 31.5% ± 1.4% compared to the hypoxic 
control (100%). The mean hypoxic EGFP fluorescence was 
suppressed to 29.4% ± 1.6% of the hypoxic control (100%) af-
ter transfection with siRNA4. Cells transfected with scrambled 
control siRNA (nsRNA) exhibited no relevant suppression of 
hypoxic EGFP fluorescence signal (97.5% ± 2.8%) compared 
to the hypoxic control (100%). Control cells or cells transfected 
with either scrambled control siRNA (nsRNA) or HIF-1α-
targeted siRNA (siRNA3 and siRNA4) showed only basal EGFP 
fluorescence below 15% under aerobic conditions compared to 
the hypoxic control (100%).
Down-Regulation of HIF-1α Protein in HT 1080 Cells by 
Small Interfering RNA
Under normoxic conditions, low basal expression of HIF-1α 
protein was measured. Increased HIF-1α protein expression 
was observed under hypoxia (0.1% O2, 12 hours; Figure 3). In 
HT 1080 cells, the mean hypoxic HIF-1α accumulation during 
severe hypoxia was significantly reduced to 47.1% ± 9.1% after 
transfection HT 1080 cells with siRNA3 and to 35.3% ± 4.1% af-
ter transfection HT 1080 cells with siRNA4 compared to hypoxic 
Figure 1. Downregulation of HIF-1a mRNA expression by HIF-1a-
targeted siRNA in HT 1080 human fibrosarcoma cells. Quantitative RT-
PCR was performed to quantify the expression of the HIF-1a gene (n = 3, 
mean ± SEM). Expression of HIF-1a mRNA was measured 16 hours after 
transfection of HT 1080 tumor cells with HIF-1a-targeted siRNA (siRNA3 
and siRNA4) or scrambled control siRNA (nsRNA). Untreated HT 1080 
control cells were defined as 100% and used as a reference for quantifica-
tion. Tansfection of HT 1080 cells with HIF-1a-targeted siRNA (siRNA 3 
and siRNA4) and scrambled control siRNA caused a reduced expression 
of the HIF-a mRNA (mean ± SEM of n = 3, *p < 0.05). HIF-1a gene expres-
sion in HT 1080 cells transfected with HIF-1a-targeted siRNA (siRNA 3 and 
siRNA4) was also significantly reduced compared to HT 1080 cells trans-
fected with scrambled control siRNA.
Abbildung 1. Herunterregulation der HIF-1a-mRNA-Expression durch 
HIF-1a-targeted siRNA in humanen HT-1080-Fibrosarkomzellen. Die 
HIF-1a-Genexpression wurde mit einer quantitativen Real-time-Poly-
merasekettenreaktion bestimmt (n = 3, mean ± SE). Die HIF-1a-mRNA-
Expression wurde bestimmmt 16 Stunden nach Transfektion der HT-
1080-Tumorzellen mit HIF-1a-targeted siRNA (siRNA3 and siRNA4) oder 
Kontrol siRNA (nsRNA). Unbehandelte HT-1080-Zellen wurden als Refe-
renz (100%) zur Quantifkation definiert. Transfektion der HT-1080-Zellen 
mit HIF-1a-targeted siRNA (siRNA3 and siRNA4) und Kontroll-siRNA (ns 
siRNA) verursacht eine reduzierte HIF-a-mRNA-Expresssion (Mittelwert 
± SE, n = 3, *p < 0.05). Die HIF-1a-Gen-Expression in HIF-1a-targeted-
siRNA-(siRNA3 und siRNA4-)transfizierten Zellen war signifikant redu-
ziert verglichen mit Kontroll-siRNA-(nsRNA-)transfizierten HAT-1080-
Zellen (Mittelwert ± SE, n = 3, *p < 0.05). 
Figure 2. Effects of siRNA on HIF-1-dependent transcriptional activa-
tion in HT 1080 human fibrosarcoma cells. HT 1080 human fibrosarcoma 
cells were pre-treated with 133 nM small interfering RNA for 4 hours and 
transferred for 12 hours to hypoxic (0.1% O2) or maintained in aerobic 
(20% O2) conditions.Transfection HT 1080 cells with HIF-1a-targeted siR-
NA (siRNA3 and siRNA4) inhibits the hypoxic activation of HRE-mediated 
EGFP fluorescence in stably transfected HT 1080 human fibrosarcoma 
cells. Hypoxic HT 1080 control cells were defined as 100% and used as a 
reference for quantification (mean ± SEM of n = 3, *significant difference 
from hypoxic control, p < 0.05).
Abbildung 2. Einfluss von siRNA auf die HIF-1-abhängige transkriptio-
nelle Aktivierung in humanen HAT-1080-Fibrosarkomzellen. Humane 
HAT-1080-Fibrosarkom-Zellen wurden 4 Stunden lang mit 133 nM Small 
Interfering RNA vorbehandelt und anschließend 12 Stunden lang unter 
hypoxischen (0,1% O2) bzw. aeroben (20% O2) Bedingungen inkubiert. 
Transfektion der HAT-1080-Zellen mit HIF-1a-targeted siRNA (siRNA3 
and siRNA4) inhibiert die hypoxische Aktivierung des HIF-1-regulierten 
Promotors und „green fluorescent protein“ (GFP) als Marker (5HRE-GFP) 
in stabil transfizierten humanen HT-1080-Fibrosarkomzellen. Hypoxische 
HAT-1080-Kontrollzellen wurden definert als 100% und wurde als Refe-
renz zur Quantifikation verwendet (Mittelwert ± SE, n = 3, *signifikanter 
Unterschied p < 0,05).
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control HT 1080 tumor cells (100%) transfected with scrambled 
control siRNA (ns siRNA, 0.1% O2; p < 0.05).
Clonogenic Survival
Treatment of HT 1080 cells with HIF-1α-targeted siRNA (siRNA3 
and siRNA4) in a concentration of 133 nM or scrambled control 
siRNA (nsRNA) did not significantly affect the survival frac-
tion under normoxic or under hypoxic conditions (Figure 4). 
Scrambled control siRNA also did not affect the clongenic sur-
vival and has no effect on the radiosensitivity of HT 1080 cells in 
air compared to nontransfected HT 1080 cells (Figure 5).
In the absence of siRNA3 and siRNA4, survival after sin-
gle-dose irradiation was significantly increased under hypoxic 
conditions compared to normoxia (p < 0.05). HIF-1α-targeted 
siRNA (siRNA3 and siRNA4) enhanced significantly radiation 
treatment efficacy under severely hypoxic conditions com-
pared to tumor cells treated with scrambled control siRNA (ns 
siRNA) (Figure 6, Table 1).
OER’ was calculated at 50%, 37%, and 10% survival levels 
obtained from calculated α and β values. For three indepen-
dent experiments, the mean OER’ values were calculated. The 
reduction of OER’ values was significant on all survival levels 
after treatment with HIF-1α-targeted siRNA (siRNA3 and 
 siRNA4), except for the survival level 10% after incubation with 
siRNA4 (Table 2).
Discussion
HIF-1 inhibition has been shown to slow tumor growth in in 
vitro and in vivo tumor models [16, 39] and to act synergis-
tically with other treatment modalities such as radiotherapy 
[25]. Kung et al. [16] identified chetomin as a small molecule 
blocking the HIF pathway. Chetomin disrupts the structure of 
the CH1 domain of p300, a transcriptional coactivator, thereby, 
Figure 3a and 3b. Downregulation of HIF-1a protein levels by small 
interfering RNA in HT 1080 human fibrosarcoma cells. HT 1080 human 
fibrosarcoma cells were pre-treated with 133 nM small interfering RNA 
for 4 hours and transferred for 12 hours to hypoxic (0.1% O2) or main-
tained in aerobic (20% O2) conditions. HIF-1a levels were evaluated by 
Western blot (a mean ± SEM of n = 5, *significant difference at p < 0.05). 
Cells transfected with scrambled control siRNA (nsRNA) under hypoxic 
conditions were defined as 100% and used as a reference for quantifica-
tion. Transfection HT 1080 cells with HIF-1a-targeted siRNA (siRNA3 and 
siRNA4) caused a reduced hypoxic accumulation of HIF-1a protein. Rep-
resentative Western blot (b).
Abbildung 3a und 3b. Herunterregulation des HIF-1a-Proteins in huma-
nen HAT-1080-Fibrosarkomzellen durch Small Interfering RNA. Humane 
HAT-1080-Fibrosarkom-Zellen wurden 4 Stunden lang mit 133 nM Small 
Interfering RNA vorbehandelt und anschließend 12 Stunden lang unter 
hypoxischen (0,1% O2) bzw. aeroben (20% O2) Bedingungen inkubiert. 
HIF-1a-Protein wurde mit Western Blot detektiert. Transfektion der HAT-
1080-Zellen mit HIF-1a-targeted siRNA (siRNA3 and 4) verursacht eine 
reduzierte hypoxische Akkumulation von HIF-1a. Mit Kontroll-siRNA 
transfizierte hypoxische HAT-1080-Zellen, wurden als 100% definiert und 
als Referenz zur Quantifikation verwendet (a Mittelwert ± SE, n = 5, *si-
gnifikanter Unterschied p < 0,05). Repräsentativer Western Blot (b).
Figure 4. Survival Fraction (SF) under normoxic conditions or under hy-
poxic conditions after treatment with HIF-1a-targeted siRNA in HT 1080 
human fibrosarcoma cells. Effects of treatment with in vitro hypoxia (0.1% 
O2) and/or HIF-1a-targeted siRNA (siRNA3 and siRNA4) or scrambled 
control siRNA (nsRNA) on the  survival fraction (SF) of HT 1080 human 
fibrosarcoma cells. SF of untreated HT 1080 human fibrosarcoma cells 
incubated under normoxic condition were defined as 100% and used as 
a reference for quantification. (mean ± SEM of n = 3, *significant differ-
ence between respective HIF-1a-targeted siRNA [siRNA3 and siRNA4] or 
scrambled control siRNA [nsRNA]).
Abbildung 4. Survival Fraction (SF) in humanen HAT-1080-Fibrosar-
komzellen unter normoxischen oder hypoxischen Bedingungen nach 
Behandlung mit HIF-1a-targeted siRNA. Der Einfluss von Hypoxie in 
vitro (0–1% O2) und/oder HIF-1a-targeted siRNA (siRNA3 und siRNA4) 
oder Kontroll-siRNA (nsRNA) auf die Survival Fraction (SF) von huma-
nen HAT-1080-Fibrosarkomzellen. Die SF von unbehandelten humanen 
HAT-1080-Fibrosarkomzellen, welche unter normoxischen Bedingungen 
inkubiert wurden, wurde als 100% definiert und diente als Referenz zur 
Quantifizierung (Mittelwert ± SE, n = 3, *signifikanter Unterschied zwi-
schen HIF-1a-targeted siRNA [siRNA3 and siRNA4] bzw. Kontroll-siRNA 
[nsRNA]; p < 0,05).
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precluding its interaction with HIF and attenuating hypoxia-
inducible transcription. We previously showed in a human 
fibrosarcoma cell line that indirect HIF-1 targeting with chet-
omin suppresses the transcriptional response to hypoxia and 
reduces hypoxic radioresistance in vitro [25].
Lövey et al. [18] could also show in A431 tumor-bearing 
SCID mice treated rHuEPOalpha a decreased tumoral HIF-
1alpha expression and an increased the efficacy of radiotherapy 
in vivo. In the present study, we investigated the effects of di-
rect, specific targeting of HIF-1α via RNA interference under 
conditions of radiobiologically relevant tumor hypoxia. HIF-1α 
expression was silenced using two differently designed HIF-1α-
targeted siRNAs (siRNA3 and siRNA4) that were transfected 
into HT 1080 cells. We could demonstrate that knockdown of 
hypoxia-induced expression of HIF-1α with RNA interference 
increased radiosensitivity of hypoxic cells and strongly sup-
pressed HIF-1α m-RNA expression compared to untreated hu-
man fibrosarcoma cells or HT 1080 cells treated with scrambled 
control siRNA.
The calculated modified oxygen enhancement ratio 
(OER’) values were reduced after incubation with chetomin 
Figure 5. Clonogenic survival after treatment with/without scrambled 
control siRNA (nsRNA) under normoxic conditions in HT 1080 human fi-
brosarcoma cells. Clonogenic survival of HT 1080 human fibrosarcoma 
cells after radiation treatment in air (20% O2): HT 1080 cells were trans-
fected with scrambled control siRNA (nsRNA) 16 hours prior radiation 
treatment (n = 3, mean ± SEM). Scrambled control siRNA (nsRNA) has no 
effect on the radiosensitivity of HT 1080 cells in air compared to non-
transfected HT 1080 cells.
Abbildung 5. Klonogene Überleben in humanen HAT-1080-Fibrosar-
komzellen nach Behandlung der Zellen mit/ohne Kontroll-siRNA (nsRNA) 
unter normoxischen Bedingungen (20% O2). Klonogenes Überleben von 
humanen HAT-1080-Fibrosarkom-Zellen nach Bestrahlung unter nor-
moxischen Bedingungen (20% O2). HAT-1080-Zellen wurde mit Kontroll-
siRNA transfiziert (n = 3, Mittelwert ± SE) und nachfolgend 16 Stunden 
lang unter normoxischen Bedingungen inkubiert. Anschließend wur-
den die Zellen bestrahlt. Kontroll-siRNA (nsRNA) beeinflusst nicht die 
Strahlensensitivität von HAT-1080-Zellen unter normoxischen Bedin-
gungen (20% O2) verglichen mit unbehandelten, d.h. nicht transfizierten 
HAT-1080-Zellen. Figure 6a and 6b. Clonogenic survival after treatment with HIF-1a-
targeted siRNA under normoxic and hypoxic conditions in HT 1080 hu-
man fibrosarcoma cells. Clonogenic survival of HT 1080 human fibro-
sarcoma cells after radiation treatment in air (20% O2) or hypoxia (0.1% 
O2): HT108 cells were transfected with HIF-1a-targeted siRNA (a siRNA3, 
b siRNA4) or scrambled control siRNA (nsRNA) 4 hours prior to hypoxia 
(n = 3, mean ± SEM). HT 1080 cells were cultured for 12 hours under hy-
poxia/normoxia and in the presence of 133 nM HIF-1a-targeted siRNA 
(siRNA3 and siRNA4) or scrambled control siRNA (nsRNA). siRNA3 (a) and 
siRNA4 (b) has no effect on the radiosensitivity of HT 1080 cells in air, but 
increases radiosensitivity under hypoxic conditions.
Abbildung 6a und 6b. Klonogene Überleben in humanen HAT-1080-
Fibrosarkomzellen nach Behandlung der Zellen mit HIF-1a-targeted siR-
NA, bzw. Kontroll-siRNA (nsRNA) unter normoxischen bzw. hypoxischen 
Bedingungen (20% O2). Das klonogene Überleben von humanen HAT-
1080-Fibrosarkom Zellen wurde nach Bestrahlung unter normoxischen 
(20% O2) bzw. hypoxischen Bedingungen (0,1% O2) bestimmt (n = 3, 
Mittelwert ± SE). HAT-1080-Zellen wurden 4 Stunden lang mit HIF-1a-
targeted siRNA (a siRNA3, b siRNA4) und Kontroll-siRNA (nsRNA) vorbe-
handelt und anschließend 12 Stunden lang unter hypoxischen (0,1% O2) 
bzw. aeroben Bedingungen (20% O2) inkubiert. siRNA3 (a) and siRNA4 
(b) hat keinen Effekt auf die Radiosensitivität von HAT-1080-Zellen un-
ter Normoxie (20% O2), erhöht aber die Radiosensitivität unter Hypoxie 
(0,1% O2).
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Nevertheless, these results indicate that selective inhibiton 
of the hypoxic HIF-1 pathway by downregulation of HIF1α-
protein via HIF-1α-targeted siRNA treatment is as effective 
as treatment with chetomin as a small molecule blocking the 
HIF pathway. Chetomin, however, also had a cytotoxic effect in 
aerobic and, in particular, in hypoxic HT 1080 cells. In contrast 
HIF-1α-targeted siRNA had no cytotoxic effect in aerobic or 
hypoxic HT 1080 cells in the clonogenic assay compared with 
untreated HT 1080 cells or cells transfected with scrambled 
control siRNA.
One explanation for the apparently more specific action of 
the siRNA approach is the chetomin-induced disruption of the 
interaction of HIF-1 with the transcriptional coactivator p300 
as a mechanism of action. HIF-1 is only one of many transcrip-
tion factors requiring p300 as a cofactor, such as nuclear factor-
κB and activating protein-1 [15]. Blocking p300 with chetomin 
may induce inhibition of activation of other transcription fac-
tors relevant to radiosensitivity. In contrast HIF-1α-targeted 
siRNA directly suppresses HIF-1α m-RNA expression and, 
therefore, the hypoxic accumulation of HIF-1α. This is one ex-
planation why blocking HIF-1 activity with HIF-1α-targeted 
siRNA enhances radiosensitivity more selectively in hypoxic 
tumor cells than chetomin.
Yang et al. [39] could demonstrate that suppression of 
HIF-1α by using small interfering RNA (siRNA) results in a 
decrease of cell proliferation and increase of chemosensitivity 
of pancreatic cancer cells in vitro and in vivo. RNA interfer-
ence (RNAi) of HIF-1 is an effective strategy for inhibiting 
tumor cell growth, and both tumor and normal cells can be 
the target for RNAi-based anticancer treatment [27]. Further-
more HIF-1α is an important component of the apoptotic sig-
naling machinery and selective ablation of HIF-1α protein ex-
pression by RNA interference led to a reduction of caspase-3 
activity and reduction in the number of apoptotic cells after 
hypoxia [19].
The success of HIF-1 inhibition in vivo depends on other 
factors of the tumor microenvironment such as glucose metab-
olism and pH [24, 26] and potentially on the ability of a strategy 
to eliminate virtually all HIF-1 function as cell mixing experi-
ments described by Williams et al. [37] indicated that 1% of 
cells with intact HIF-1 function within a tumor are sufficient 
to preserve tumor growth. Recently, Gillespie et al. [8] demon-
strated that treating gliomas grown in mouse flank with siRNA 
against HIF-1α by intratumoral injection resulted in a signifi-
cant reduction in tumor growth. Nevertheless, intratumoral 
injection of small interfering RNA in tumors is not useful in 
all tumor entities. Another therapeutical approach blocking 
HIF-1α activation is the use of short hairpin RNA (shRNA). 
Therapeutic application of shRNA, however, is also problem-
atic as is it involves permanent changes in cellular DNA. Kung 
et al. [16] demonstrated that pharmacological inhibition of HIF 
activation with chetomin in vivo could slow tomor growth, sug-
gesting that there is a therapeutic potential for inhibition of HIF 
function in vivo.
in the previous study and HIF-1α-targeted siRNA in the cur-
rent study on all survival levels (50%, 37%, and 10%). HIF-1α-
targeted siRNA3 reduced the OER’ compared to HT 1080 cells 
transfected with scrambled control siRNA (nsRNA), from 2.25 
to 1.06 , from 2.04 to 1.12 and from 1.68 to 1.25 at the 50%, 
37%, and 10% clonogenic survival levels, respectively. Treat-
ment with HIF-1α-targeted siRNA4 reduced the modified 
oxygen enhancement ratio (OER’) compared to HT 1080 cells 
transfected with scrambled control siRNA (nsRNA), from 2.25 
to 1.11 , from 2.04 to 1.21 and from 1.68 to 1.45 at the 50%, 37%, 
and 10% clonogenic survival levels, respectively. Chetomin, in 
comparison, reduced OER’ from 2.02 to 1.27, from 1.86 to 1.22 
and from 1.49 to 1.06 at the 50%, 37%, and 10% clonogenic sur-
vival levels, respectively. Taken together, HIF-1α-targeted siR-
NA and chetomin effectively radiosensitize hypoxic HT 1080 
cells, whereas the radiosensitivity of normoxic cells remains 
unaffected [25]. The clongenic assay does not distinguish be-
tween the different types of cell death (i.e., cell cycle arrest, pro-
grammed cell death). Further experiments are necessary to un-
derstand completely the molecular aspects of hypoxia-induced 
radioresistance and the role of the HIF-1 pathway.
Table 2. Modified oxygen enhancement ratio (OER´) derived from clono-
genic survival curves after irradiation at oxygen concentrations of 20% 
(AIR) or 0.1% (hypoxia = HYP) following treatment with HIF-1a-targeted 
siRNA (siRNA3 and siRNA4) where indicated. Mean ± SEM of n = 3; *sig-
nificant difference between HIF-1a-targeted siRNA (siRNA3/siRNA4) and 
control conditions (ns siRNA).
Tabelle 2. Eine modifizierte Oxygen Enhancement Ratio (OER´) wurde 
abgeleitet aus den Überlebenskurven nach Bestrahlung mit verschieden 
Sauerstoffkonzentrationen (20% [AIR] oder 0.1% [Hypoxia = HYP]) und 
Transfektion mit HIF-1a-targeted siRNA (siRNA3 und siRNA4). Mittelwert 
± SE, n = 3; *signifikanter Unterschied zwischen HIF-1a-targeted siRNA 
(siRNA3/siRNA4) und Kontrollbedingungen (ns siRNA).
Survival 
level
OER´ (HYP/
AIR)
OER´ (HYPsiRNA3/
AIR siRNA3)
OER´ (HYPsiRNA4/
AIR siRNA4)
10% 1.68 ± 0.08 1.25* ± 0.17   1.45 ± 0.07
37% 2.04 ± 0.23 1.12* ± 0.12 1.21* ± 0.11
50% 2.25 ± 0.34 1.06* ± 0.12 1.11* ± 0.13
Table 1. Survival fraction (SF) after irradiation at oxygen concentrations 
of 20% (air) or 0.1% (hypoxia = hyp) following treatment with HIF-1a-
targeted siRNA (siRNA3 and siRNA4) or scrambled control siRNA (nsRNA). 
Mean of n = 3; *significant difference between HIF-1a-targeted siRNA 
(siRNA3/siRNA4) and control conditions (ns siRNA).
Tabelle 1. Survival Fraction (SF) nach Bestrahlung mit verschieden 
Sauerstoffkonzentrationen (20% [air] oder 0.1% [hypoxia = hyp]) und 
Transfektion mit HIF-1a-targeted siRNA (siRNA3 und siRNA4). Mittel-
wert, n = 3; *signifikanter Unterschied zwischen HIF-1a-targeted siRNA 
siRNA3/siRNA4) und Kontrollbedingungen (ns siRNA).
SF
2 Gy 5 Gy 10 Gy
nsRNAair/siRNA3air 0.497/0.515 0.079/0.072 0.002/0.001
nsRNAair/siRNA4air 0.497/0.600 0.079/0.083 0.002/0.002
nsRNAhyp/siRNA3hyp 0.974/0.530* 0.330/0.150* 0.061/0.033*
nsRNAhyp/siRNA4hyp 0.974/0.607* 0.330/0.211* 0.061/0.040*
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Conclusion
Our results indicate that the selective inhibition of HIF-1 acti-
vation by using HIF-1α-targeted siRNA treatment reduces hy-
poxic radioresistance in vitro as effectively as a pharmacologic 
approach with chetomin as a small molecule blocking the HIF 
pathway. Pharmacological therapeutics targeting pathogno-
monic changes in cancer cells are potential canidatates for clini-
cal use in cancer therapy and using siRNA to reduce HIF-1α 
levels in tumors may be of interest as a clinical treatment option 
in selected tumor entities.
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